The evaluation of a drug candidate's pharmacokinetic (PK) properties, while critical for the success of a drug, has traditionally been excluded from the early drug development process, in large part due to the cost of assays and the difficulty predicting PK properties from structures.
Exploring Avenues of Predicting Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is a major cause of acute liver dysfunction and remains one of the most challenging adverse drug reactions encountered in clinical practice.
Sustained Drug Exposure Drives Efficacy in Mice: PK/PD Analysis of Corallopyronin A against Wolbachia using Physiologically Based Absorption Modeling
Corallopyronin A (CorA) depletes essential Wolbachia endosymbionts of filarial nematodes and is therefore a promising candidate for treating the neglected tropical diseases lymphatic filariasis and onchocerciasis.
Toxicity of Some Natural Products in the Treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects mainly peripheral joints because of inflammation of the synovial membrane.
Integrating In Silico Modeling Into Undergraduate Education To Enhance Students Competency in Biopharmaceutics and Pharmacokinetics
Pharmacokinetics and biopharmaceutics are core components of pharmacy education, providing the scientific foundation for drug development and therapeutic application.
Strategies for Pediatric Dose Derivation From Population Pharmacokinetic Models
Health authorities worldwide require clinical studies in children to ensure scientifically rigorous and consistent dosing.
Quantification of the Exposure of Consumers and Hairdressers to Formaldehyde and Oxalic Acid After Application of Hair Straightening Products Containing Glyoxylic Acid
Glyoxylic acid (GA), the active ingredient of heat-activated hair straightening products (GHSPs) has been discussed in the context of acute kidney injury (AKI) via oxalic acid (OA) crystal formation and of heat-decomposition resulting in release of formaldehyde.
A Multivariate Ann-CCD Integrative Model Using Cellulose Based Polymers for the Development of Osmotically Controlled Push-Pull Dexibuprofen Tablets and Its Predictive Pharmacokinetic Modeling
The biocompatible macromolecules play a pivotal role in enhancing the performance of various drug delivery systems.
In Silico Predictions for ADME and Toxicology
Advances in computational modeling are transforming how scientists predict a compound’s Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) profiles.
In Silico Toxicokinetics
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling is a major driver of drug success, controlling pharmacokinetic behavior, therapeutic effectiveness, and safety.
In Silico Prediction of Solubility, Permeability, and Metabolism
This chapter presents a comprehensive review of in silico techniques for the prediction of solubility, permeability, and metabolism—critical determinants of drug candidates’ pharmacokinetic and safety profiles during drug discovery and development.
Physiologically Based Pharmacokinetic Modeling of Cefotaxime To Inform Pediatric Dosing in Renal Impairment
Cefotaxime (CFT) is a broad spectrum, third-generation cephalosporin antibiotic prescribed for the treatment of severe infections, yet dosing guidelines for pediatric with renal impairment is scarce.
Why Next-Generation Mechanistic Models will Transform Drug Discovery: Integrating Efficacy and Safety
Drug discovery remains constrained by high attrition rates and the fragmented evaluation of exposure, efficacy, and safety.
Animal-Free Skin Sensitization Testing: In Chemico and In Silico Integrated Approach
The increasing prohibition of animal testing for cosmetic products has driven the development of alternative approaches to ensure consumer safety.
In vitro Drug-Like Properties Evaluation of the New Positive Allosteric Modulators of EAAT2 Glutamate Transporter
Evaluation of drug-like properties in vitro is critical in identifying viable candidates for new central nervous system (CNS) drugs.
Physiologically Based Pharmacokinetic and Drug–Drug Interaction Modeling of Efavirenz, Etravirine, and Saquinavir in Prostate Cancer
Prostate cancer remains one of the most prevalent malignancies worldwide, with high mortality in advanced and metastatic stages.
Sex-Related Differences in Physiologically-Based Biopharmaceutics Modeling
Physiologically based pharmacokinetic (PBPK) and physiologically-based biopharmaceutics (PBBM) modeling are valuable tools in drug development, allowing mechanistic predictions of drug absorption and disposition.
2025 AAPS 360 Annual Meeting: Highlights in In Vitro Release and Dissolution Testing and Oral Biopharmaceutics Modeling
This manuscript highlights key sessions from the In Vitro Release and Dissolution Testing (IVRDT) and Oral Biopharmaceutics and Absorption Modeling (OBAM) communities at the 2025 AAPS PharmSci 360 Annual Meeting (November 9–12, San Antonio, TX).
Model-Based Virtual Clinical Trial Reveals Renal Impairment and Body Size as Key Determinants of Pharmacokinetic Variability and Drug-Drug Interaction Risk in Propranolol Therapy
Propranolol (PROP) is a non-selective β-blocker widely prescribed for cardiovascular and neurological disorders.
Impact of Preclinical Verification in Physiologically Based Pharmacokinetic Modelling for First-in-Human Predictions: Application of a Published Model Building Strategy for Five Compounds
Physiologically based pharmacokinetic modelling is routinely used in the pharmaceutical industry and has an impact on drug labels.